Continuous glucose monitoring (CGM) of changes in the glucose levels in the interstitial fluid (ISF) in the subcutaneous tissue is a diagnostic option that allows patients with diabetes to optimize their metabolic control. 1,2 Over the past decade, different types of needle sensors from 3 manufacturers became commercially available: Medtronic (Northridge, CA), 3 Abbott Diabetes Care (Alameda, CA), 4 and DexCom (San Diego, CA). 5 The amperometric enzymatic measuring principle allows all these CGM systems to measure the rate of glucose consumption by an enzyme. This measurement principle depends on the rate of glucose flow from the ISF to the enzyme immobilized on the sensor surface through membranes covering the sensor. A stable sensor signal requires a constant diffusion rate of glucose; this however usually is not the case in situ as biofouling of the membrane takes place. This not well-defined process includes the deposition of cells or proteins to the sensor surface that become additional barriers hampering glucose diffusion. This causes signal drift and changes in the intensity of the sensor raw signal within days. To overcome such shortcomings, glucose sensors were developed that couple the amperometric measurement with the micro-dialysis principle. The latter allows generation of a fluid with a glucose concentration that is closely correlated to that in the ISF but which is practically protein-free. The glucose signals generated by such systems were accurate and stable over time. 6,7 To date, only one microdialysis system (GlucoDay; Menarini, Florence, Italy) is available on the market in Europe. 8 This is mainly used for research purposes. Affinity sensors employ a different measuring principle; these are based on the reversible binding of the analyte to a specific receptor. In the case of glucose, the protein 6957D STXXX10.